Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 3, 2015
Previous Article Next Article

Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth

Author affiliations

Abstract

Axitinib (AXT) is a potent and selective orally administered inhibitor of the vascular endothelial growth factor receptors 1–3 that contribute to the pathogenesis of solid tumors. The goal of the present study was to enhance the antiangiogenic and antitumor effects of AXT under hypoxia. Here we developed spherical polypeptide-coated hybrid liposomal nanoparticles (P-LNP/AXT) with a narrow size distribution and high loading efficiency. The cytotoxic effects of P-LNP/AXT on cancer cells were lower than those of AXT, and the human cancer cell lines SCC7, BT-474, and SH-SY5YP efficiently incorporated P-LNP/AXT. However, these formulations were not significantly internalized by the mouse macrophage cell line RAW 264.7, suggesting that they could evade the reticuloendothelial system. Western blotting analysis showed a significant increase in the level of expression of hydroxy-HIF-1α when cells were treated with P-LNP/AXT. The growth of tumors in mice treated with P-LNP/AXT was significantly inhibited compared with controls. Further, elevated levels of caspase-3 and poly (ADP-ribose) polymerase and reduced levels of platelet/endothelial cell adhesion molecule 1 (PECAM1, CD31) and Ki-67 in tumor cells suggested that tumor cells underwent apoptosis and that angiogenesis was inhibited within the tumor. Thus, P-LNP/AXT shows promise for cancer chemotherapy by inhibiting tumor angiogenesis.

Graphical abstract: Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth

Back to tab navigation

Article information


Submitted
31 Aug 2014
Accepted
28 Oct 2014
First published
29 Oct 2014

J. Mater. Chem. B, 2015,3, 408-416
Article type
Paper

Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth

J. Y. Choi, T. Ramasamy, T. H. Tran, S. K. Ku, B. S. Shin, H. Choi, C. S. Yong and J. O. Kim, J. Mater. Chem. B, 2015, 3, 408
DOI: 10.1039/C4TB01442A

Social activity

Search articles by author

Spotlight

Advertisements